Generated by AI
Immutep Limited is a clinical-stage biotechnology company developing immunotherapies that regulate immune-cell activity for cancer and autoimmune diseases. Its research is centered on Lymphocyte Activation Gene-3, or LAG-3, an immune-control pathway that can be used to stimulate immune responses against tumors or moderate harmful immune activity. The company’s leading product candidate, eftilagimod alfa, is a soluble LAG-3 protein designed to activate antigen-presenting cells and support broader anti-tumor immune responses, including in combination with other cancer treatments. Immutep Limited also develops additional LAG-3-focused candidates, including IMP761, an immune-modulating therapy being evaluated for autoimmune conditions, and antibody-based programs intended to affect disease-associated T cells. The company operates within the biotechnology and life sciences markets, serving the pharmaceutical and healthcare sectors through clinical development, research collaborations, and potential therapeutic applications in oncology and immunology. Headquartered in Sydney, Australia, Immutep Limited represents a specialized participant in the development of next-generation immune-regulating medicines.
WebsiteAustralia Square
Sydney, NSW, 2000
Australia
The latest articles about IMMP.
SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,788,796) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office (USPTO). With this latest grant, Immutep now holds five United States patents within this patent family. The portfolio has expanded p
Summary of Sep 28's posts. Generated by AI.
Summary of Apr 16's posts. Generated by AI.
Summary of Sep 28's posts. Generated by AI.
Investors talking about IMMP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.